International Law firm Hogan Lovells is representing Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of obesity, in filing for voluntary relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. Orexigen also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.

The team representing Orexigen is led by Hogan Lovells Business Restructuring and Insolvency practice group head and partner Chris Donoho, counsel Christopher Bryant and senior associate John Beck. The team also consisted of associates Sean Feener and Eric Einhorn.